Seer (NASDAQ:SEER) Stock Rating Upgraded by Canaccord Genuity Group

Seer (NASDAQ:SEER) was upgraded by research analysts at Canaccord Genuity Group to a “strong-buy” rating in a research note issued on Monday, Marketbeat reports. The firm currently has a $4.00 price target on the stock. Canaccord Genuity Group’s target price suggests a potential upside of 115.05% from the company’s previous close.

A number of other research firms have also recently commented on SEER. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Seer in a report on Tuesday, April 21st. TD Cowen raised shares of Seer to a “strong-buy” rating in a report on Monday, April 13th. Two analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Seer currently has a consensus rating of “Buy” and a consensus price target of $4.00.

Seer Trading Down 4.6%

NASDAQ:SEER opened at $1.86 on Monday. The stock has a market capitalization of $104.94 million, a PE ratio of -1.45 and a beta of 1.63. The firm’s 50 day moving average is $1.83 and its 200 day moving average is $1.91. Seer has a 12 month low of $1.65 and a 12 month high of $2.41.

Seer (NASDAQ:SEER) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.03. The company had revenue of $4.20 million for the quarter, compared to analysts’ expectations of $4.60 million. Seer had a negative net margin of 443.96% and a negative return on equity of 26.04%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SEER. Occudo Quantitative Strategies LP purchased a new position in Seer in the 2nd quarter valued at approximately $25,000. Marshall Wace LLP purchased a new position in Seer in the 4th quarter valued at approximately $85,000. Quadrature Capital Ltd purchased a new position in Seer in the 4th quarter valued at approximately $101,000. Barclays PLC grew its stake in Seer by 685.0% in the 4th quarter. Barclays PLC now owns 60,717 shares of the company’s stock valued at $111,000 after buying an additional 52,982 shares in the last quarter. Finally, Corient Private Wealth LLC purchased a new position in Seer in the 4th quarter valued at approximately $116,000. 75.20% of the stock is currently owned by hedge funds and other institutional investors.

About Seer

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.